XML 31 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment and Related Information

6 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment and Related Information

(15) SEGMENT AND RELATED INFORMATION

The Company’s business is aligned with how the Chief Operating Decision Maker reviews performance and makes decisions in managing the Company.  The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.

Segment revenue and operating income (loss) were as follows during the periods presented:

		Diagnostics				Other				Total
Three months ended December 31, 2017
Revenues		$	179.2			$	14.8			$	194.0
Depreciation and amortization			11.7				1.4				13.1
Segment operating income (loss)			34.6				(30.2	)			4.4
Three months ended December 31, 2016
Revenues		$	183.9			$	12.6			$	196.5
Depreciation and amortization			11.5				1.4				12.9
Segment operating income (loss)			32.1				(15.1	)			17.0
Six months ended December 31, 2017
Revenues		$	358.0			$	26.2			$	384.2
Depreciation and amortization			23.5				2.8				26.3
Segment operating income (loss)			68.6				23.3				91.9
Six months ended December 31, 2016
Revenues		$	348.9			$	25.0			$	373.9
Depreciation and amortization			19.3				2.8				22.1
Segment operating income (loss)			62.0				(39.4	)			22.6

		Three months ended								Six months ended
		December 31,								December 31,
		2017				2016				2017				2016
Total operating income for reportable segments		$	4.4			$	17.0			$	91.9			$	22.6
Unallocated amounts:
Interest income			0.4				0.3				0.8				0.6
Interest expense			(0.7	)			(2.6	)			(1.7	)			(3.3	)
Other			(0.4	)			(2.6	)			(0.7	)			(3.8	)
Income from operations before income taxes			3.7				12.1				90.3				16.1
Income tax provision			(28.4	)			6.2				(22.8	)			11.4
Net income			32.1				5.9				113.1				4.7
Net loss attributable to non-controlling interest			—				—				(0.1	)			—
Net income attributable to Myriad Genetics, Inc.    stockholders		$	32.1			$	5.9			$	113.2			$	4.7

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Name:	us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration